Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [29] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the prior year [30] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30] - Non-GAAP net income for Q4 2025 was $160 million or $1.34 per diluted share, compared to $149 million or $1.19 per diluted share in the prior year [31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - Global specialty products group sales grew by 14.6%, driven by strong performance in implants and biomaterials [33] - Global technology group sales grew by 8.4%, with significant contributions from practice management software [33] Market Data and Key Metrics Changes - U.S. dental merchandise sales growth reflected continued market share gains, with January 2026 sales showing good momentum [18] - International dental merchandise sales grew by 9.2% in constant currencies, with strong growth across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - U.S. medical distribution sales grew by 4.9%, reflecting strong growth in home solutions, while international dental equipment sales grew by 13.9% [32][33] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [12][13] - The rollout of the global e-commerce platform, henryschein.com, is underway, with expectations to complete the rollout to U.S. Dental and Canadian customers in Q1 2026 [14] - The company is focusing on innovative solutions to enhance patient care and operational efficiency, including partnerships with Amazon Web Services for AI integration [14][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the U.S. dental market, with positive trends in patient traffic and dentist investments in technology [51][54] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to ongoing value creation initiatives [58] - Management noted that the international dental equipment market is performing well, with broad-based growth across many countries [23][32] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [35] - Operating cash flow for Q4 2025 was $381 million, compared to $204 million in Q4 2024, driven by working capital management [36] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from value creation initiatives will be more heavily weighted to the back half of the year, with some lumpiness expected in the first half [43][44] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases [46][48] Question: Durability of dental market performance - Management confirmed that the U.S. dental market is stable and leaning positively, with good feelings among dentists regarding investments in technology [50][54] Question: Sustainability of implant performance - Management expressed optimism about the implant market, particularly in Europe, while noting that U.S. growth is currently less than 5% [72][73]

Financial Data and Key Metrics Changes - Global sales for Q4 2025 reached $3.4 billion, reflecting a sales growth of 7.7% compared to Q4 2024, with constant currency sales growth of 5.8% and a 1.9% increase from foreign currency exchange [28][29] - GAAP operating margin for Q4 2025 was 4.76%, a decrease of 10 basis points from the prior year, while non-GAAP operating margin was 7.42%, relatively flat compared to the prior year [29] - Q4 2025 GAAP net income was $101 million or $0.85 per diluted share, compared to $94 million or $0.74 per diluted share in the prior year [30] - Non-GAAP net income for Q4 2025 was $160 million or $1.34 per diluted share, compared to $149 million or $1.19 per diluted share in the prior year [31] Business Line Data and Key Metrics Changes - Global distribution and value-added services group sales grew by 7.0%, with U.S. dental merchandise sales increasing by 3.6% and U.S. dental equipment sales growing by 10.6% [32] - International dental merchandise sales grew by 9.2%, driven by growth across Southern and Eastern Europe, Germany, Brazil, and Canada [32] - Global specialty products group sales increased by 14.6%, with strong performance in implants and biomaterials, particularly in Germany, Brazil, and France [22][33] Market Data and Key Metrics Changes - U.S. medical distribution sales grew by 4.9%, reflecting strong growth in home solutions, while international dental equipment sales grew by 13.9% [32][33] - The U.S. dental market showed signs of stability and positive trends, with patient traffic remaining stable and a slight positive lean observed [15][51] - International equipment sales growth was broad-based, benefiting from currency exchange rates [21] Company Strategy and Development Direction - The company is executing its 2025-2027 BOLD+1 strategic plan, with non-GAAP operating income from high-growth, high-margin businesses approaching 50% of total operating income [11] - Significant progress has been made in rolling out the global e-commerce platform, henryschein.com, and partnerships with Amazon Web Services for AI integration [12][26] - The company aims to achieve over $200 million in operating income improvement through value creation initiatives, including cost savings and capturing incremental gross margin opportunities [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the U.S. dental market and the positive sentiment among dentists regarding investments in new technologies [51] - The company anticipates earnings growth to be more heavily weighted towards the second half of 2026 due to the timing of value creation initiatives [58] - Management noted that the overall market for dental implants is stable, with positive momentum in international markets, particularly in Germany [72] Other Important Information - The company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share, totaling $200 million [35] - Operating cash flow for Q4 2025 was $381 million, compared to $204 million in Q4 2024, driven by effective working capital management [36] Q&A Session Summary Question: Guidance on operating income improvement plan - Management indicated that the benefits from the $125 million run rate will be more heavily weighted to the back half of the year, with some lumpiness expected in the quarters [41][42] Question: Growth in specialty value implants - Management noted strong growth in specialty value implants and indicated stable pricing within the market, with no unusual price increases observed [45][48] Question: Durability of market performance - Management confirmed that the U.S. dental market is stable and leaning positively, with good feelings among dentists about investing in new technologies [50][51] Question: Sustainability of implant performance - Management expressed optimism about the sustainability of implant performance, particularly in international markets, while noting that U.S. growth is more stable but less robust [67][72]

Core Insights - Envista Holdings Corp. (NYSE:NVST) experienced a significant stock price increase of 23.4% week-on-week, reaching a nearly three-year high, driven by strong earnings performance and a return to profitability [1][3] Financial Performance - The company reported a net income of $47 million for the previous year, a turnaround from a net loss of $1.1 billion in 2024 [3] - Year-on-year sales increased by 8% to $2.7 billion, up from $2.5 billion [3] - In Q4, net profit surged by 2,642% to $32.9 million from $1.2 million in the same quarter the previous year [3] - Q4 sales grew by 15% to $750.6 million, compared to $652.9 million in the same period last year [3] Strategic Focus - The CEO emphasized a disciplined focus on growth, operations, and employee development, highlighting positive growth across all major businesses and geographies [4] - The company returned $166 million to shareholders through share repurchases [4] Future Outlook - For the current year, Envista aims to grow core sales by 2 to 4% and expects adjusted EBITDA to increase by 7 to 13% [5] - Adjusted diluted earnings per share are projected to be between $1.35 and $1.45 [5]

Core Insights - PioCreat is showcasing its Chairside 3D printing solutions for dentistry at AEEDC Dubai 2026, marking its first appearance in Dubai and emphasizing its focus on the Middle Eastern market [1][2] Company Overview - PioCreat 3D was founded in 2015 and specializes in developing professional 3D printing systems for dentistry, offering integrated hardware, software, and material solutions to enable efficient and precise digital workflows for dental practices and laboratories [8] Product Highlights - The PioNext Mini features a portable all-in-one design that combines printing and curing in a compact case (200 × 170 × 241 mm), allowing for true chairside production in space-constrained clinics. It can produce ceramic crowns in just 10 minutes using the ACF Fast Vat, while the HDF Clear Vat provides high transparency results without polishing [4] - The PioNext Ultra is an upgraded printer that enhances stability and output consistency for stack printing applications. PioCreat also presents additional products such as Sky 2025, DJ68, and UV02, providing a comprehensive overview of its 3D printing systems for the dental sector [5] Exhibition Experience - PioCreat's booth features interactive displays and hands-on product demonstrations, allowing visitors to assess the print quality of finished dental parts and consult with application specialists on clinical workflows, material selection, and practice integration [6] Future Vision - PioCreat aims to strengthen its partnerships in global markets by providing reliable, user-oriented solutions for digital dentistry, reaffirming its commitment to offering efficient and accessible 3D printing technology to dentists [7]

Core Insights - PioCreat is participating in AEEDC Dubai 2026, marking its first appearance in Dubai and introducing its chairside dental 3D printing solutions to the Middle East market [1][2] Company Overview - PioCreat, founded in 2015, specializes in developing professional dental 3D printing systems, providing integrated hardware, software, and material solutions to enhance digital workflows in dental clinics and laboratories [8] Product Highlights - The PioNext Mini features a compact design (200×170×241 mm) that allows for chairside production, with capabilities for 10-minute ceramic crown fabrication and high transparency results [4] - The PioNext Ultra is an upgraded printer designed for improved stability and output consistency in batch printing applications, alongside other products like Sky 2025, DJ68, and UV02 [5] Exhibition Experience - The PioCreat booth offers interactive displays and hands-on demonstrations, allowing visitors to assess print quality and engage in consultations regarding clinical workflows and material selection [6] Future Vision - PioCreat aims to strengthen global partnerships by providing reliable and user-oriented digital dentistry solutions, focusing on empowering dental professionals with efficient 3D printing technology [7]

Core Insights - PioCreat is participating in the AEEDC Dubai 2026, marking its first appearance in Dubai and showcasing its dental 3D printing solutions to the Middle Eastern market [1][2] - The event serves as a significant milestone for PioCreat in terms of global expansion and commitment to digital dentistry [2] Product Features - PioCreat will present a comprehensive portfolio of dental 3D printing products during the event [3] - The PioNext Mini features an all-in-one design that combines printing and curing processes in a compact body (200×170×241 mm), enabling real patient production in space-constrained clinics [4] - The dual resin vat with ACF Fast Vat supports 10-minute ceramic crown production, while HDF Clear Vat offers high transparency and results that do not require polishing [4] - PioCreat is also introducing the upgraded PioNext Ultra for batch printing applications, along with other products like Sky 2025, DJ68, and UV02, showcasing a comprehensive solution from printing to post-curing [5] Interactive Experience - The PioCreat booth features interactive screens and product demonstrations, allowing visitors to examine the print quality of completed dental parts and engage in detailed discussions with application experts about clinical workflows, material selection, and application integration [6] Future Vision - PioCreat aims to strengthen partnerships in global markets by providing reliable, user-focused digital dentistry solutions and reaffirming its commitment to offering efficient and accessible 3D printing technology to dental professionals [7] Company Background - Founded in 2015, PioCreat 3D specializes in the development of professional dental 3D printing systems, offering integrated hardware, software, and material solutions to enhance the efficiency, precision, and accessibility of digital workflows in clinics and laboratories [8]

Group 1: Executive Appointments - Keurig Dr Pepper appointed Anthony DiSilvestro as the new CFO as the company prepares to close its JDE Peet's acquisition and split into two independent companies [2] - Shake Shack's finance chief, Katherine Fogertey, will transition to a senior adviser role and leave the company on March 4, 2026, while the company establishes an office of the CFO [3] - Dentsply Sirona named Michael Pomeroy as interim CFO, stepping in for Matthew Garth, who left the company after six months in the role [4] - Cheryl Paquete was appointed CFO of Terran Orbital, a Lockheed Martin subsidiary that manufactures satellites, after a long tenure in finance and business operations at Lockheed Martin [5] Group 2: Company Developments - Keurig Dr Pepper is in the process of splitting into two independent companies, indicating a significant strategic shift [2] - Shake Shack is restructuring its financial leadership by creating an office of the CFO, which will include a team of financial planning, accounting, and treasury leaders [3] - Dentsply Sirona is undergoing a leadership change with the appointment of an interim CFO, reflecting potential operational adjustments [4] - Terran Orbital continues to strengthen its leadership with the appointment of a new CFO, emphasizing its focus on satellite manufacturing [5]

Core Insights - Global equity markets experienced significant growth in Q3, with the S&P 500 rising 8.12% for the quarter and 14.83% year-to-date, while the MSCI EAFE Index increased by 4.77% for the quarter and 25.14% year-to-date [2][3] Market Performance - The S&P 500 achieved back-to-back annual returns of 26% and 25% in 2023 and 2024, respectively, with valuation metrics like the "Buffett Indicator" and CAPE-Shiller P/E at or near record highs [2] - Non-US equities, particularly European stocks, outperformed the S&P 500 year-to-date, benefiting from a weaker US dollar and a resurgence in value recognition [3][11] Fund Performance - Tweedy, Browne Funds reported year-to-date returns ranging from 15.98% for the Value Fund to 23.17% for the International Value Fund II, with the Worldwide High Dividend Yield Value Fund outperforming its benchmark [3][5] - The International Value Fund II had a return of 23.17%, trailing its benchmark, the unhedged MSCI EAFE Index, by 197 basis points [3] Portfolio Activity - The company made strategic adjustments to its portfolio, trimming or selling holdings that reached estimated value and adding to companies perceived as attractively priced, such as Berkeley Group Holdings and Breedon Group [8] - New positions were initiated in Santec Holdings and additional investments were made in companies like Dentium and Azelis Group, reflecting a focus on growth potential and reasonable valuations [8] Outlook - The company is optimistic about the resurgence of non-US equity returns and believes its funds are well-positioned for future market conditions, whether they favor non-US equities or face broader market challenges [11]

Core Viewpoint - Dentsply Sirona Inc. has faced challenges in its third-quarter performance, leading to a downgrade in its stock rating and a revised earnings outlook for 2025 [2][6]. Financial Performance - The company reported adjusted earnings of 37 cents per share for the third quarter, a significant 26.5% decrease from the previous year, falling short of the Zacks Consensus Estimate of 45 cents [3][6]. - Revenues for the quarter were $904 million, reflecting a 4.9% year-over-year decline, although this figure slightly exceeded the Zacks Consensus Estimate by 0.3% [4][6]. - The decline in revenue was primarily driven by poor performance in specific segments, particularly Orthodontic and Implant Solutions, which saw a 15% decline [4]. Strategic Response - In response to the performance issues, the company's CEO announced a return-to-growth plan aimed at improving the company's trajectory [5]. - The company has revised its 2025 EPS guidance downwards to approximately $1.60, while still anticipating sales in the range of $3.6 to $3.7 billion [5].

Core Insights - Dentsply Sirona Inc. reported weaker-than-expected third-quarter earnings and lowered guidance, leading to a decline in stock price [1][7] Financial Performance - Adjusted earnings for the third quarter were 37 cents, down from 50 cents a year ago, but above the consensus estimate of 45 cents [1] - Sales totaled $904 million, a decrease of 5% year over year, yet surpassing the consensus of $896.71 million [2] - Adjusted EBITDA margin improved by 50 basis points to 18.4%, driven by reduced operating expenses, although this was partially offset by lower sales and tariff impacts [2] Segment Performance - Revenues from Connected Technology Solutions fell by 3.9% to $259 million due to lower volumes [2] - Orthodontic and Implant Solutions sales dropped 15% to $205 million, impacted by approximately $30 million from Byte and lower implant volumes in the U.S. and China [3] Strategic Initiatives - The company is implementing a "Return-to-Growth" strategy aimed at delivering sustained, profitable growth over the next 24 months [4] - The board is taking decisive actions to improve performance, as stated by the president and CEO [4] Management Changes - CFO Matt Garth has left the company, with Leslie Varon serving as interim finance chief while a successor is sought [5] Guidance - Fiscal 2025 adjusted earnings guidance has been lowered from $1.80-$2 per share to $1.60, compared to the consensus of $1.88 [6] - The company reaffirmed its 2025 sales guidance of $3.6 billion-$3.7 billion, aligning closely with the consensus of $3.65 billion [6] Market Position - Dentsply Sirona has decided to retain Wellspect as a subsidiary, which focuses on bladder and bowel care products, positioned in a $2 billion addressable market [6][7]